Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial. (2021)
Attributed to:
Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.2021.39.15_suppl.5530
Publication URI: http://dx.doi.org/10.1200/jco.2021.39.15_suppl.5530
Type: Journal Article/Review
Parent Publication: Journal of Clinical Oncology
Issue: 15_suppl